Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. - Wikidata - awgldk - TriplyDB

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

http://www.wikidata.org/entity/Q40151883

about

Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis A user's guide to cannabinoid therapies in oncology Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life.Cannabinoids in Pediatrics.Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.Pharmacotherapy for Dravet Syndrome.Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome.Epileptic Encephalopathy in Infants and Children Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function.A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol.Guideline recommendations for diagnosis and clinical management of Ring14 syndrome-first report of an ad hoc task force.An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.Even High Doses of Oral Cannabidol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102-112; DOI: 10.1089/can.2015.0004.The potential role of cannabinoids in epilepsy treatment.Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy?Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats.Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges and future directions.Dynamic complexity measures and entropy paths for modelling and comparison of evolution of patients with drug resistant epileptic encephalopathy syndromes (DREES).Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?The Pharmacologic and Clinical Effects of Illicit Synthetic Cannabinoids.Recent advances in epilepsy.Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients.Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.Is there a role for cannabidiol in psychiatry?Building smart cannabis policy from the science up.The Use of Cannabinoids in Treating Dementia.An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol.Models for discovery of targeted therapy in genetic epileptic encephalopathies.Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases.Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines.A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans.Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol.Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. DOI: 10.1089/can.2016.0036.Natural (∆9-THC) and synthetic (JWH-018) cannabinoids induce seizures by acting through the cannabinoid CB1 receptor.Cannabidiol and Epilepsy: Sifting, Winnowing and Buzz.Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol.

P2860

Q28071794-E6BAD64A-F3C8-4731-83EB-506C9BFEED70 Q28553714-D4552AD3-24A1-4540-B9DD-4368FDFA4239 Q28818800-D1F5A8E9-D6A2-4F39-84E9-47BADB75A511 Q30376980-C3977400-5DEF-4DC1-9DDF-FDC01E2A10AC Q30842130-7B5194A1-BB64-46BE-8DD9-15B48827F2EB Q33658933-F1683343-3993-4C3B-9C6D-51669B9D45CE Q33806487-93AF5A4F-AE88-4A07-A4CA-88CEF8DFC253 Q34530386-A7C8EA28-74AC-4BCE-90C5-B0BDA45841BB Q35953476-D7AF31EA-497B-4E78-9FD2-06C058938895 Q36245909-3FFF4330-9F5C-4C53-B9C8-4D85556C4CD5 Q37182454-C06CC80D-44B5-48CE-B047-A0A63CDB8B5C Q37336806-AB7BBE04-E232-4759-9DD0-49EF0E6229D3 Q37662551-09CC3152-5B10-47F6-BBFC-FCF84023FE97 Q37747670-73B04054-FE91-4C0F-9FE3-4584C41EE69C Q38598487-06BEC094-1115-4670-9818-AB97B69BB475 Q38598503-66510465-F9A9-4084-AE01-70FD4A3810EA Q38606080-0EE54051-99D8-4DDA-B990-EFA693100AEB Q38647074-AA34B552-FB83-4884-BE0B-7150AD1F41F2 Q38687088-9D63A61E-1DC8-46CA-A2D8-89A54EC0C4D8 Q38688752-7415D4FA-A5EC-4335-A78F-414B4E7E08E0 Q38732954-757A7AC6-F539-49D4-A016-41C1C72B767C Q38748394-FA57F583-C5F9-4BB6-9759-897713A8B92D Q38949998-8BE9A5D4-6B7F-4F6C-933E-30482591E36A Q39000942-4FBA04A0-DC7D-482A-A61C-785CB2555C25 Q39006241-A26370E5-BFE0-4B53-A083-9CA86AFC64C3 Q39012173-0CA6A933-3EAD-414C-A904-9749396A0200 Q39020765-02F2680B-7D72-4237-9E7E-14FA7CA1239E Q39098495-C8E3F9E0-9E82-4CC5-924A-1ABDD7CC938B Q39131734-83E91E6A-41DE-49BE-ADD9-B3BEC0C279E5 Q39385097-4ACA246A-A320-4263-8B1B-CCDEA3BF4FD9 Q39431492-587B4DE8-685F-4FED-A346-F9C0D00E3787 Q39457643-FE1F2A2A-F5C2-4DBA-9EB4-B4B156CA4763 Q40531740-9C7F5389-8AF5-46E6-94EF-6A9E17049381 Q41003488-20F36A78-568E-4E8B-828A-B22301E4B7AD Q41016981-1C956F8D-A8AE-48FB-AC25-93DD55413255 Q41236873-04608F94-6592-4D0A-8C08-5BA28673BC16 Q41507965-C2FD178F-D87B-4053-B224-FC8EA55A279B Q41621185-C02F42D1-A79A-43CD-A9FD-864123FC9CB6 Q41720453-5DE5A2AF-64C0-4545-B236-2DE5B7DB0463 Q41808396-DB07663A-FE4B-4CCC-856D-9CE861E537C6

P2860

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

http://www.wikidata.org/entity/Q40151883

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cannabidiol in patients with t ...... en-label interventional trial.

@en

type

label

Cannabidiol in patients with t ...... en-label interventional trial.

@en

prefLabel

Cannabidiol in patients with t ...... en-label interventional trial.

@en

P1433

Q40151883-F36F81F2-15D8-46C4-9B79-D9137CD173EE

P1476

Q40151883-5E663FA0-2D6D-4265-91D6-99D96D5B01FE

P2093

Q40151883-0310F5A1-8ABA-4180-9216-04BC5CFBAD8A

Q40151883-0E7AD66B-8154-4E98-9BAB-7B439A55A800

Q40151883-10BA75A5-3C5E-4E5E-B796-64ADDBDBCA23

Q40151883-356BC595-F4A0-4DCC-97EE-1A9730015A84

Q40151883-3FD55E63-E47A-4EBE-A585-8F8EC19D5AE9

Q40151883-40CBC879-47F0-43C5-A67E-F12F928A8EEA

Q40151883-483C724F-FDB9-4944-855E-341439078B02

Q40151883-54761CC1-5B4F-4A00-A76F-A545ECFC549F

Q40151883-6114635A-9DC6-491A-9280-68459A969B75

Q40151883-6309B5B6-3E14-461F-916F-67055C7EF2AB

P304

Q40151883-0342F047-025E-4495-97C0-15D16EB6FB5F

P31

Q40151883-DB5C4FCB-D354-409B-A35E-AE93951D0585

P356

Q40151883-D41B49D0-B5BB-40C0-8752-E7E339FC8811

P433

Q40151883-B0AA376D-BBF1-49DE-86CC-B5A1DFA6B4E6

P478

Q40151883-D33FDE1F-9C89-4BC6-9288-358C904EAB9F

P50

Q40151883-23FA1A0C-1013-412D-BF8F-1BEE8E932EDE

Q40151883-49504CA9-2C22-41C9-A23E-84DF65AC16A3

P577

Q40151883-FE4CD1CD-F737-4DCE-B952-C78E4A0A9B27

P5875

Q40151883-C4A3059D-88B9-41A9-A73C-51C4E82BC286

P698

Q40151883-116C14FE-6ABA-475C-B9C3-C63C93B4B36B

P921

Q40151883-922D7AD5-3C33-4349-AAB0-146982A1C86B

Q40151883-C9F76B91-D70B-42E4-B882-6CEBB9F2DEF3

P356

S1474-4422(15)00379-8

P1433

Lancet Neurology

P1476

Cannabidiol in patients with t ...... en-label interventional trial.

@en

P2093

Angus Wilfong

http://www.w3.org/2001/XMLSchema#string

Anup Patel

http://www.w3.org/2001/XMLSchema#string

Carey A Wilson

http://www.w3.org/2001/XMLSchema#string

Daniel Friedman

http://www.w3.org/2001/XMLSchema#string

Elizabeth Thiele

http://www.w3.org/2001/XMLSchema#string

Eric Marsh

http://www.w3.org/2001/XMLSchema#string

Francis Filloux

http://www.w3.org/2001/XMLSchema#string

Ian Miller

http://www.w3.org/2001/XMLSchema#string

Jane Maclean

http://www.w3.org/2001/XMLSchema#string

Joseph Sullivan

http://www.w3.org/2001/XMLSchema#string

P304

270-278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(15)00379-8

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Judith Bluvstein

P577

2015-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288024502

http://www.w3.org/2001/XMLSchema#string

P698

26724101

http://www.w3.org/2001/XMLSchema#string

P921